EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gene and Cell Therapy for Sarcomas: A Review

Sant P Chawla, Skyler S Pang, Darshit Jain, Samantha Jeffrey, Neal S Chawla, Paul Y Song, Frederick L Hall, Erlinda M Gordon

Cancers · 27.03.2025 · 17 (7) · 1125

DOI: 10.3390/cancers17071125 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.03.2025. Verfasst von Sant P Chawla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sarcoma Oncology Center/Cancer Center of Southern California, Santa Monica, CA 90403, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The heterogeneity of sarcomas and resulting distinct sub-type specific characteristics, their high recurrence rates, and tendency for distant metastasis, continue to present significant challenges to providing optimal treatments.

Objective

To provide a comprehensive review of current literature and clinical trials in gene and cell therapies for sarcomas.

Methods

A comprehensive literature search was conducted utilizing the following databases: PubMed, Medline, Google Scholar and clinicaltrials.gov. Search terms included “gene therapy”, “cell therapy”, “NK cell therapy, “CAR-T therapy”, “virotherapy”, “sarcoma”, “gene therapy”, and “solid tumors”. Additional sources were identified through manual searching for references of relevant studies. No language restrictions were set. The NCT number, study status, condition, and phase were noted for clinical trials.

Results

There are only three gene and cell therapies for sarcomas that have been approved by a federal regulatory agency. Rexin-G: the first tumor-targeted gene therapy vector designed to target all advanced solid malignancies, including chemo-refractory osteosarcomas and soft tissue sarcomas, was approved by the Philippine FDA in 2007. Gendicine was the first oncolytic virus approved for intratumoral delivery in China in 2003. Afami-cel, an innovative chimeric antigen receptor (CAR) T cell therapy, was approved for synovial sarcoma in the United States in 2024. Other promising therapies are discussed in the text.

Conclusions

The future of gene and cell therapy for sarcomas holds great promise, as research moves to late-stage clinical development. The integration of gene and cell therapies into standard sarcoma treatment protocols has the potential to significantly improve the quality of life and outcomes for patients with this rare and challenging group of cancers.

Schlagwörter

Stichwörter der Autor:innen

CAR-T therapycell therapygene therapynatural killer cell therapysarcomasolid tumorsvirotherapy

Autor:innen und Institutionen

  • Sarcoma Oncology Center/Cancer Center of Southern California, Santa Monica, CA 90403, USA.
  • Aveni Foundation, Santa Monica, CA 90403, USA.
  • NKGen Biotech, Inc., Santa Ana, CA 92705, USA.
  • Delta Next-Gene, LLC, Santa Monica, CA 90405, USA.

Zitieren

APA

Chawla, S. P., Pang, S. S., Jain, D., Jeffrey, S., Chawla, N. S., Song, P. Y., Hall, F. L., & Gordon, E. M. (2025). Gene and Cell Therapy for Sarcomas: A Review. Cancers, 17(7), 1125. https://doi.org/10.3390/cancers17071125

Vancouver

Chawla SP, Pang SS, Jain D, Jeffrey S, Chawla NS, Song PY, et al. Gene and Cell Therapy for Sarcomas: A Review. Cancers. 2025;17(7):1125. doi:10.3390/cancers17071125

BibTeX
@article{Chawla2025,
  author = {Chawla, Sant P and Pang, Skyler S and Jain, Darshit and Jeffrey, Samantha and Chawla, Neal S and Song, Paul Y and Hall, Frederick L and Gordon, Erlinda M},
  title = {Gene and Cell Therapy for Sarcomas: A Review},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {7},
  pages = {1125},
  doi = {10.3390/cancers17071125}
}
Kostenlos starten →